Status:

RECRUITING

Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients

Lead Sponsor:

University of Michigan Rogel Cancer Center

Conditions:

Skin Basal Cell Carcinoma

Eligibility:

All Genders

65+ years

Phase:

NA

Brief Summary

This clinical trial evaluates whether active surveillance (AS) is a safe and comfortable alternative to standard of care (SOC) treatment for elderly patients with low-risk basal cell carcinoma (LR-BCC...

Detailed Description

PRIMARY OBJECTIVES: I. To identify the baseline characteristics of patients who are willing and able to enroll in an randomized controlled trial (RCT) examining acceptability of AS versus (vs.) SOC. ...

Eligibility Criteria

Inclusion

  • Subject of any gender aged ≥ 65 years at the time of enrollment
  • Patient at University of Michigan Department of Dermatology (UMichDD)
  • Willing and able to provide informed consent
  • Willing and able to comply with the protocol requirements
  • Histopathologic diagnosis of one or more LR-BCC(s) within 2 months of enrollment. LR-BCC is defined here as biopsy proven primary (not recurrent) BCC of any morphologic subtype; \< 2cm in size; with or without marginal involvement on histopathology; and located on the trunk or extremities excluding pretibial surface, hands, feet, nail units, and ankles (corresponding to area L in the Mohs Appropriate Use Criteria, representing the lowest risk areas)

Exclusion

  • Individuals who are immunocompromised per judgement of investigator (examples include but are not limited to patients on immunosuppressive medications such as prednisone \> 10 mg daily, uncontrolled HIV, and organ transplant recipients on immunosuppressive therapy)
  • Individuals who expect to relocate and will be unable to return to UMichDD for clinical follow-up visit(s)
  • Individuals with a genetic syndrome predisposing to development of basal cell carcinoma

Key Trial Info

Start Date :

October 8 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 28 2025

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06539468

Start Date

October 8 2024

End Date

December 28 2025

Last Update

April 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States, 48109